乳腺癌中枢神经系统转移的开发性治疗:当前格局与未来展望
乳腺癌是中枢神经系统转移的第二大原因,HER2阳性或三阴性乳腺癌患者风险最高且预后较差。本文综述乳腺癌脑转移的生物学新发现、迄今临床进展,并提出研究性治疗的合理方向。
要点
- HER2阳性或三阴性乳腺癌患者发生中枢神经系统转移的风险最高。
- 尽管接受局部和全身治疗,这类患者通常预后较差。
- 开发性治疗需加深对生物学细微差异及血脑屏障与新化合物相互作用的认识。
核心结论
- 乳腺癌中枢神经系统转移的开发性治疗需改进对其生物学细微差异及血脑屏障与新化合物相互作用的认识。
研究设计与样本
- 本文为综述,回顾乳腺癌脑转移相关生物学发现及迄今临床进展,并提出研究性治疗的合理方向。
主要发现
- 乳腺癌是中枢神经系统转移的第二大原因。
- HER2阳性或三阴性乳腺癌患者发生中枢神经系统转移的风险最高,且尽管接受局部和全身治疗,通常预后较差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of survival in a subset of patients presenting with metastatic breast cancer. Patients with HER2 positive (HER2+) or triple negative breast cancer are at highest risk of developing CNS metastasis, and typically experience a poor prognosis despite treatment with local and systemic therapies. Among the obstacles ahead in the realm of developmental therapeutics for breast cancer CNS metastasis is the improvement of our knowledge on its biological nuances and on the interaction of the blood–brain barrier with new compounds. This article reviews recent discoveries related to the underlying biology of breast cancer brain metastases, clinical progress to date and suggests rational approaches for investigational therapies.
引用
- Costa R, Carneiro BA, Wainwright DA, et al. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol. 2017. PMID: 28177431. doi:10.1093/annonc/mdw532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。